Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad

INTERVENTION: Intervention 1: Intervention group: nanocurcumin capsule 40mg, two capsule twice daily for two weeks then 1 capsule twice daily for 2 weeks. Intervention 2: Control group:all standard measures will be performed for patient. CONDITION: COVID‐19 pneumonia. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on clinical, paraclinical and laboratory findings. Drug adverse reaction. Timepoint: daily. Method of measurement: patient interview and file. Fever. Timepoint: daily. Method of measurement: thermometer. Radiologic response. Timepoint: one month after the beginning of the treatment. Method of measurement: lung HRCT. SECONDARY OUTCOME: Length of hospital stay. Timepoint: at the end of treatment course. Method of measurement: patient file. Patient clinical outcome. Timepoint: at the end of the treatment. Method of measurement: patient file. INCLUSION CRITERIA: laboratory or radiologic or clinical diagnosis of mild to moderate COVID‐19 age between 18‐65y sign of the written consent Not simultaneous participating in other clinical trials